kidneys has generated concern among psychiatrists, and proposals have been made that routine deter minations of serum lithium and serum TSH should be supplemented with control of the kidney function through regular determinations of serum creatinine,
glomerular filtration rate, and renal concentrating ability, as well as through kidney biopsy in certain circumstances.
The choice of laboratory investigations must, how ever, depend on whether the purpose of the investi gation is to collect data for scientific research or to guard the individual patient's safety. A scientific programme may include any investigative procedures that serve to test currently interesting hypotheses and to create data bases which will permit examination of problems emerging in the future. When, on the other hand, the individual patient is concerned, one must for each examination weigh its value as a safeguard and a guide for therapeutic decisions against its incon venience to patient and clinic and its consumption of resources.
A considerable number of studies have now been published about lithium effects on the kidneys; kidney morphology has been examined in more than 150 and kidney function in more than 1000 lithium treated patients. It is the aim of the present paper to assess the outcome of these investigations and to dis cuss on this basis which laboratory methods are best suited to guard the patient's health and safety.
Outcome of the kidney studies
The glomerular filtration rate is largely unaffected by lithium treatment (except during severe poisoning).
Filtration rateslowerthan 70 per centof thenormal are infrequent and values lower than 50 per cent of the normal extremely rare. Examination of large patient groups has failed to disclose patients with filtration rates which were so low that survival was threatened. The risk of progressive renal insufficiency with ter minal azotemia is remote even in patients given lithium for many years.
Tubular function is often affected during lithium treatment. A number of studies have revealed impair ment of renal water reabsorption, leading to the development of polyuria and polydipsia. These side effects may be troublesome for the patients (increased thirst, nycturia, possibly weight gain), but they do not lead to lowering of the renal lithium clearance or rise ofthe serum lithium concentration, and they are not in themselves dangerous. However, because of the lowered renal concentrating ability the patients are apt to become dehydrated iffluid intake is restricted or Water reabsorption is often impaired during lithium treatment, and the concentrating ability of the kidneys may be followed quantitatively through determin ations of urine osmolality after thirst (by with holding fluids in a test) or after administration of vasopressin or vasopressin analogues. Examinations of this kind are clearly of interest for clinics doing research on the treatment and prevention of lithium induced polyuria, but the question is whether such examinations provide information of sufficient value for therapeutic decisions, for example for decisions about discontinuing lithium treatment, to justify the effort and inconvenience of their inclusion in a routine monitoring program.
Even if in some patients the maximum osmolality of the urine may fall to a low value, this does not mean that these patients are going to develop renal in sufficiency or die prematurely, and it does not con stitute grounds for discontinuing prophylactically effective and otherwise well tolerated lithium treat ment. The findings signify merely that the patients should respond readily to feelings of thirst and avoid situations involving risk of dehydration. Regular determinations of maximum urine osmolality may serve to identify patients for whom this is particularly important, but admonitions about drinking and avoidance of dehydration should be given to all patients in lithium treatment, and it is our view that lithium treatment can be monitored adequately with out regular determinations of the concentrating ability of the kidneys.
It has been suggested that the renal concentrating ability might be followed as an indicator of the occurrence of morphological changes and that kidney biopsy should be considered when the maximum urine osmolality reaches a low value. There is, how ever, no evidence that the morphological changes which may be induced by lithium have any functional or prognostic significance other than, possibly, the lowered concentrating ability itself, and patients and clinics may well be spared such investigations.
Laboratory examinations
By far the most important laboratory examination during lithium treatment is regular determination of the serum lithium concentration. The absolute value of the serum concentration is a measure of the degree to which the organism is exposed to lithium, and it is this concentration which should be adjusted to, and then maintained at, a level which in the individual patient provides a maximum of therapeutic and prophylactic benefit with a minimum of inconvenience and risk. Moreover, since at steady-state there is a dynamic equilibrium between lithium dosage, lithium clearance and serum lithium concentration, change of the serum lithium concentration with unaltered dosage is a sensitive indicator of change of the renal lithium clearance (and, under most circumstances, of the glomerular filtration rate). A consistent rise of serum lithium shows that there has been a fall of the lithium clearance and should lead to further examinations.
In order to serve these two purposes reliably the serum lithium concentration should be determined under standardized circumstances, for example in the morning 12 hours ( Â±1 hour) after the last intake of lithium and under steady-state conditions, that is at least 4â€"5 days after start of treatment and after dosage changes. If blood samples are drawn under different conditions, serum lithium values may be misleading and may give rise to unwarranted and possibly harm ful changes ofthe lithium dosage.
When blood samples are drawn for determination of the serum lithium concentration, the serum creatinine concentration may be determined in addition without extra inconvenience to the patients and at small extra cost. The serum creatinine concentration serves as an indicator of the glomerular filtration, but attention should again be focused on change of the concentra tion, since a consistently rising serum creatinine con centration can be a danger sign even at levels which are below the upper normal limit.
Under most circumstances the serum lithium con centration and the serum creatinine concentration vary in parallel when the lithium dosage is constant, because the renal lithium clearance is a fairly constant fraction of the glomerular filtration rate. One may therefore ask whether determinations of serum creatinine are worth the, admittedly small, extra cost and effort. We think that the following reasons speak in favour of including serum creatinine determinations among the routine tests:
(i) Assessment of the serum creatinine concen tration does not, as does assessment of the serum lithium concentration that take place over weeks or days, for example as a result of intercurrent disease, with fever, start of treatment with diuretic drugs, loss of fluid and salt during heavy sweating, etc. It is therefore important that patients and relatives are instructed about such risk situations and are informed about clinical signals of impending lithium poisoning. The appearance of any such signs and symptoms should lead to clinical examination and determination of the serumlithium concentration.
Conclusion
Safe and effective lithium treatment must be based on proper selection of patients, on thorough in struction of patients and relatives about treatment managementand precautions, and on careful clinical observajion so that ineffectual dosages and adverse reactions can bedetectedearly.
The choice of laboratory' tests must depend on whether they servea scientific purpose or are used to guard the individual patient's safety and health. We suggest here that extensive examinations of glomer ular filtration rate and renal concentrating ability are of limited value for the latter purpose and that lithiumtreatment can be monitoredadequately through determinations of serum lithium and serum creatinine every two to four months and of serum TSH every six months. The appearanceof unexpected signs and symptoms should lead to closer clinical and laboratory examination.
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lithium concentration, rely on precise timing of the blood sample in relation to the last intake of lithium and is therefore independent of such patient co operation.
(ii) Use of change in the serum lithium concen tration as an indicator of change in kidney function presupposes that the lithium dosage has been kept constant; assessment ofchange in the serumcreatinine concentration is subject to no suchcondition.
(iii) Determinations of serum lithium and serum creatinine are both subject to analytical variation; it is useful to have two independentindicators of changein renal function.
(iv) Psychiatrists are perhaps more accustomed to pay attention to the absolute value of the serum lithium concentration than to its changes; a rise of serum creatinine may therefore, rather than a rise of serum lithium, lead them to think of changes in the kidney function and to seeknephrological assistance.
Determination of serum lithium and sctÃ¼m creatinine at intervaLsduring lithiLim treatment serves to disclose gradual changesin kidney function. Such regular laboratory control has the added benefit of serving as a frame for the close contact between patient and physician that is essential for optimum treatment outcome, and this is perhaps not the least important function of the visits to the clinic. Their frequency may vary individually, but intervals of two to four, months are appropriate for many patients.
Examination of patients at intervals of two to four months does not guard against rises of the serum 
